Trial Profile
A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06840003 In Patients With Malignant Gliomas
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs EOS-200271 (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 20 May 2020 Results published in the Investigational New Drugs
- 13 Jan 2020 Status changed from completed to discontinued.
- 23 Jan 2019 Status changed from active, no longer recruiting to completed.